[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
Next Generation Neurology
March 2016

Antisense Oligonucleotides for Duchenne Muscular DystrophyWhy No Neurologist Should Skip This

Author Affiliations
  • 1Department of Neurology, University of Michigan, Ann Arbor
  • 2A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor
JAMA Neurol. 2016;73(3):259-260. doi:10.1001/jamaneurol.2015.4011

Duchenne muscular dystrophy (DMD) was described by the disease’s namesake in the mid-19th century. Over time, the phenotype, genetics, and pathogenesis of this fatal disorder of muscle degeneration have been well described. An understanding of DMD has become universally taught in medical schools and common knowledge among neurologists, physiatrists, and other physicians. Despite our now long-standing understanding of the disease, the development of new, meaningful treatments for these patients has been disappointing. The standard of care remains corticosteroids; however, this may evolve in the near future, as promising new therapies for DMD focusing on exon skipping have been described. Understanding these new therapies highlights both the exciting future of neuromuscular medicine yet also underscores significant challenges ahead. Moreover, the emergence of these treatments recently spurred the US Food and Drug Administration (FDA) to draft guidance for industry in the realm of developing drugs for treating dystrophinopathies.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×